BRAF and lung carcinoma: In 2011, the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society introduced papillary subtype of lung adenocarcinoma coexisting with very high TTF-1 expression (90–100%) and 5% BRAF mutation [21].